Lymphoma

Patients with blood cancer may develop serious infections after transplants, but a T-cell therapy may improve symptoms and side effects.

There were some monumental FDA approvals in the cancer space during 2022 — here’s a roundup of our most-read agency decisions of the year.

Data demonstrate that iberdomide alone or in combination with other treatments may be a promising option for patients with relapsed/refractory lymphoma.

Patients with relapsed/refractory follicular lymphoma — a group that traditionally has limited treatment options — now have a new bispecific antibody available.

Robert Atteberry never gave up, even after three cancer diagnoses, and has found a motivation and passion for competing in triathlons during survivorship.

Years after I went through mesothelioma, my husband was diagnosed with cancer, causing a reversal in the patient-caregiver roles.

The Food and Drug Administration granted a priority review to epcoritamab for certain patients with large B-cell lymphoma, an aggressive type of blood cancer.

The Food and Drug Administration approved Adcetris plus chemotherapy for pediatric patients with classical high-risk Hodgkin lymphoma.

A novel drug, MRT-2359, will be studied in a phase 1/2 trial for patients with MYC-driven cancers.

Compared with tissue biopsies, liquid biopsies performed with blood samples may inform cancer teams of a patient’s increased risk for blood cancers, although all patients may not have this risk.

I made a point to continue baking a weekly challah bread after I was diagnosed with blood cancer, and it proved to be therapeutic.

Patients with orbital indolent B-cell lymphoma, a rare type of blood cancer, may be able to have fewer side effects and less cancer treatment costs by undergoing a lower dose of radiation that still has similar responses to the standard.

After being diagnosed with lymphoma, I scheduled consultations with three oncologists, but only one provided me with the hope I needed.

From Blink-182’s bassist Mark Hoppus discussing his cancer experience in an upcoming book to Bruce Sutter, a Hall-of-Fame pitcher and Cy Young winner, dying of the disease, here’s what’s happening in the cancer space this week.

Investigators of an expanded clinical trial have administered an investigational CAR-T cell therapy to the first patient with blood cancer.

The CAR T Together initiative is geared toward improving the development of allogeneic CAR-T cell therapies for patients with cancer.

From “Chicago Med” actress Marlyne Barrett announcing her gynecologic cancer diagnosis to a New York City-based news team walking in honor of their former news director who died of glioblastoma, a form of brain and spinal cord cancer, here’s what’s happening in the cancer space this week.

Patients with blood cancer who have higher levels of neurofilament light chains — which indicate brain injury — were found to be more likely to develop neurotoxicity after CAR-T cell therapy, according to recent research.

I used to love October, but after being diagnosed with cancer on Oct. 12 — twice — I dread the month.

The Food and Drug Administration issued a statement about the incidence of new cases of rare cancers that have occurred in the scar tissue around breast implants.

Actress Jane Fonda announced that she has been diagnosed with non-Hodgkin lymphoma and will be receiving chemotherapy to treat the blood cancer.

The combination treatment demonstrated survival and safety results similar to those of chemotherapy for patients with advanced, untreated follicular lymphoma.

The FDA has allowed the manufacturer of emavusertib to continue a phase 1/2 study investigating effects of the treatment in patients with lymphoma.

From ESPN analyst Dick Vitale announcing he is cancer-free months following a lymphoma diagnosis to a Speedo-clad race in South Africa to raise awareness for cancer, here’s what’s happening in the oncology space this week.

A representative of the company developing the investigational CAR-T cell therapy noted that they hypothesize that the combination “has the potential to further enhance efficacy and provide patients with a chemotherapy-sparing, second-line treatment option.”